S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

BioNTech Short Interest Ratio and Short Volume

-64.23 (-18.67%)
(As of 12/6/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
6.77 million shs
Average Volume
3.19 million shs
Market Capitalization
$67.86 billion
P/E Ratio
Dividend Yield

BioNTech (NASDAQ:BNTX) Short Interest Data

Current Short Volume
Previous Short Volume
Change Vs. Previous Month
Dollar Volume Sold Short
$799.03 million
Short Interest Ratio / Days to Cover
Last Record Date
November, 15 2021
Outstanding Shares
Percentage of Shares Shorted
Today's Trading Volume
Average Trading Volume
Today's Volume Vs. Average
Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling BioNTech ?

Sign up to receive the latest short interest report for BioNTech and its competitors with MarketBeat's FREE newsletter.

BioNTech (NASDAQ:BNTX) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
11/15/20213,190,000 shares $799.03 million +25.1%N/A1 $250.48
10/29/20212,550,000 shares $710.76 million +0.4%N/A0.7 $278.73
10/15/20212,540,000 shares $629.11 million +10.9%N/A0.6 $247.68
9/30/20212,290,000 shares $625.15 million -2.6%N/A0.5 $272.99
9/15/20212,350,000 shares $834.84 million +10.9%N/A0.6 $355.25
8/31/20212,120,000 shares $697.88 million +2.4%N/A0.5 $329.19
8/13/20212,070,000 shares $781.05 million +32.7%N/A0.5 $377.32
7/30/20211,560,000 shares $512.23 million -23.2%N/A0.5 $328.35
7/15/20212,030,000 shares $448.79 million -9.0%N/A0.7 $221.08
6/30/20212,230,000 shares $499.25 million -21.5%N/A0.7 $223.88
6/15/20212,840,000 shares $619.60 million -8.4%N/A0.9 $218.17
5/28/20213,100,000 shares $632.40 million -18.6%N/A1.1 $204.00
5/14/20213,810,000 shares $688.81 million -0.5%1.6%1.4 $180.79
4/30/20213,830,000 shares $688.06 million -19.4%1.6%1.5 $179.65
4/15/20214,750,000 shares $629.85 million -0.2%2.0%2.4 $132.60
3/31/20214,760,000 shares $497.13 million +25.3%2.0%2.5 $104.44
3/15/20213,800,000 shares $392.46 million +4.7%1.6%1.8 $103.28
2/26/20213,630,000 shares $407.76 million -1.9%1.5%1.3 $112.33
2/12/20213,700,000 shares $436.71 million -20.9%1.5%1.1 $118.03
1/29/20214,680,000 shares $514.80 million -28.8%1.9%1.2 $110.00
1/15/20216,570,000 shares $695.43 million +11.7%2.7%1.6 $105.85
12/31/20205,880,000 shares $493.57 million -7.4%2.4%1.5 $83.94
12/15/20206,350,000 shares $687.51 million -9.7%2.6%1.6 $108.27
11/30/20207,030,000 shares $773.23 million +13.9%2.9%2 $109.99
11/15/20206,170,000 shares $654.02 million +1.3%2.6%2 $106.00

Institutional Investors Shorting BioNTech (NASDAQ:BNTX)

This table shows institutional investors, funds, and major shareholders that have reported short positions as of their most recent reporting period. Most commonly, these investors have purchased put options on shares of BioNTech. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Reporting DateInvestor NameShares Shorted (Previous)Shares Shorted (Current)Position ChangePosition Size
12/1/2021Balyasny Asset Management LLC13,00065,000+400.0%$17.74 thousand
11/17/2021Centiva Capital LPN/A1,020N/A$278.00
11/16/2021Jane Street Group LLC302,600754,000+149.2%$205.83 thousand
11/16/2021CTC LLCN/A1,077N/A$29.35 thousand
11/16/2021Two Sigma Investments LP14,30021,600+51.0%$5.90 thousand
11/16/2021Two Sigma Securities LLC1,00012,500+1,150.0%$3.41 thousand
11/16/2021UBS Group AG284,000287,300+1.2%$78.43 thousand
11/16/2021Millennium Management LLC25,00060,000+140.0%$16.38 thousand
11/16/2021Citadel Advisors LLC767,6001,945,100+153.4%$530.99 thousand
11/16/2021Centiva Capital LPN/A1,020N/A$278.00
11/15/2021CSS LLC IL13,00034,000+161.5%$9.28 thousand
11/15/2021Balyasny Asset Management LLC13,00065,000+400.0%$17.74 thousand
11/15/2021Caas Capital Management LP18,50018,500No Change$5.05 thousand
11/12/2021PEAK6 Investments LLC81,600497,000+509.1%$135.68 thousand
11/12/2021Caption Management LLCN/A12,500N/A$3.41 thousand
11/12/2021Capital Fund Management S.A.24,50089,000+263.3%$24.30 thousand
11/12/2021Wolverine Trading LLC113,000182,500+61.5%$50.63 thousand
11/10/2021Goldman Sachs Group Inc.112,50030,000-73.3%$8.19 thousand
11/10/2021HAP Trading LLC17,00030,000+76.5%$793.00
11/10/2021Citigroup Inc.85,000104,900+23.4%$28.64 thousand
11/9/2021Concourse Financial Group Securities Inc.N/A0N/A$0.00
11/5/2021IMC Chicago LLCN/A254,400N/A$69.45 thousand
10/22/2021DekaBank Deutsche GirozentraleN/A1,000N/A$0.00
10/19/2021CTC LLCN/A1,077N/A$29.35 thousand
10/14/2021XR Securities LLCN/A6,400N/A$242.00

BioNTech (NASDAQ:BNTX) Short Interest Frequently Asked Questions

What is BioNTech's current short interest?

Short interest is the volume of BioNTech shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 3,190,000 shares of BNTX short. Learn More on BioNTech's current short interest.

What is a good short interest ratio for BioNTech?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BioNTech currently has a short interest ratio of 1.0. Learn More on a good short interest ratio for BioNTech

Which institutional investors are shorting BioNTech?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioNTech: Balyasny Asset Management LLC, Centiva Capital LP, Jane Street Group LLC, CTC LLC, Two Sigma Investments LP, Two Sigma Securities LLC, UBS Group AG, Millennium Management LLC, Citadel Advisors LLC, Centiva Capital LP, CSS LLC IL, Balyasny Asset Management LLC, Caas Capital Management LP, PEAK6 Investments LLC, Caption Management LLC, Capital Fund Management S.A., Wolverine Trading LLC, Goldman Sachs Group Inc., HAP Trading LLC, Citigroup Inc., Concourse Financial Group Securities Inc., IMC Chicago LLC, DekaBank Deutsche Girozentrale, CTC LLC, and XR Securities LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is BioNTech's short interest increasing or decreasing?

BioNTech saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,190,000 shares, an increase of 25.1% from the previous total of 2,550,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does BioNTech's short interest compare to its competitors?

0.00% of BioNTech's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to BioNTech: Amgen Inc. (2.07%), Moderna, Inc. (4.17%), Gilead Sciences, Inc. (0.00%), Biogen Inc. (1.40%), Seagen Inc. (1.80%), Bio-Techne Co. (1.26%), Novozymes A/S (0.00%), argenx SE (1.96%), Repligen Co. (3.22%), and QIAGEN (1.57%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.06 billion), S&P Global Inc. ($8.74 billion), Charter Communications, Inc. ($5.66 billion), Canadian Pacific Railway Limited ($5.43 billion), Wayfair Inc. ($4.23 billion), Palo Alto Networks, Inc. ($3.46 billion), DoorDash, Inc. ($3.41 billion), Teladoc Health, Inc. ($2.84 billion), Etsy, Inc. ($2.76 billion), and Zscaler, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short BioNTech stock?

Short selling BNTX is an investing strategy that aims to generate trading profit from BioNTech as its price is falling. BioNTech's stock is trading down $64.23 today. To short BioNTech stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that BioNTech will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against BioNTech?

A short squeeze for BioNTech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BNTX, which in turn drives the price of the stock up even further.

How often is BioNTech's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BNTX, twice per month. The most recent reporting period available is November, 15 2021.

This page was last updated on 12/7/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.